Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
about
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectiveImpact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosisSerum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapyPharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients.Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levelsTrough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis.Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignanciesTherapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.Safety, Efficacy, and Exposure-Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach.Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review.Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation.Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers.Utility of voriconazole therapeutic drug monitoring: a meta-analysis.Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levels.Comparing Azole Plasma Trough Levels in Lung Transplant Recipients: Percentage of Therapeutic Levels and Intrapatient VariabilityVoriconazole and the liver.Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.Voriconazole treatment in adults and children with hematological diseases: can it be used without measurement of plasma concentration?
P2860
Q27009221-66AB912A-7AB2-4F32-923C-C0D7277CCA8CQ30491969-75EBC7D7-9A5D-4612-9E7F-E3491C991EB5Q34020402-03EC548E-72C4-40A3-843A-641AFF40A806Q34413393-60DE282F-7377-4AC2-807D-21719D7444CFQ35105949-4BBC64E2-6E2C-42D6-917F-FE50FC8469F5Q35169112-3C1CEA8B-CAFB-48C9-AB4A-A7C7BEE1C2E3Q35954530-FC922EDC-2B1F-43F8-8C9D-FC385DA23CDBQ36608562-C143983E-4B31-421C-9D60-EF6A84177913Q36969780-2697BCB5-6786-4A7E-82A2-F0A641802CD0Q37688257-BC66DBC2-DEE9-4DA7-A586-AF5438950C69Q37693296-CB5DA2EA-DEE2-4680-8AED-54FA6A435A5FQ38284468-3C788002-A490-49A6-BC88-28242BE00BF0Q38362057-32947482-2BB6-40A5-9C7D-43D22C179B13Q38526795-6D879DBC-332F-47ED-965F-A985783F8914Q39196770-616308D1-4CBC-4933-ACC2-35F07D5DBFD4Q39479653-27E41001-7E4D-4859-9D65-ADC299BC24CFQ40255550-A92A6414-39D9-44C9-AA80-14EC1633AE1EQ40317932-F9F482D2-843D-4094-A587-5E1FD8C24462Q40679884-C4519B73-F4FA-4A3D-AF9F-3890A50BE72BQ40842732-97D21EDC-3A24-4062-BF33-C476D099AFBBQ41991703-61E89D5C-1B7D-469A-8F23-DCC3810001D9Q42027433-DCD0A17C-4ABF-4D64-BC88-F3C6E5AA12ABQ46119145-9FB8FDE6-ECAA-4874-A157-5A59FE1CF4DBQ49385523-AA40A5C8-40A9-468E-A7F3-3EEF97EC784B
P2860
Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Monitoring trough voriconazole ...... l life multicentre experience.
@en
Monitoring trough voriconazole ...... l life multicentre experience.
@nl
type
label
Monitoring trough voriconazole ...... l life multicentre experience.
@en
Monitoring trough voriconazole ...... l life multicentre experience.
@nl
prefLabel
Monitoring trough voriconazole ...... l life multicentre experience.
@en
Monitoring trough voriconazole ...... l life multicentre experience.
@nl
P2093
P2860
P1433
P1476
Monitoring trough voriconazole ...... l life multicentre experience.
@en
P2093
Barbora Weinbergerova
Iva Kocmanova
Jana Winterova
Jiri Mayer
Lucie Buresova
Ludmila Malaskova
Martina Lengerova
Martina Toskova
Michal Kouba
Monika Rolencova
P2860
P304
P356
10.1111/J.1439-0507.2012.02186.X
P577
2012-03-19T00:00:00Z